UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 6-K

 

Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16

Under the Securities Exchange Act of 1934

 

For the Month of November 2020

 

001-36203

(Commission File Number)

 

CAN-FITE BIOPHARMA LTD.

(Exact name of Registrant as specified in its charter)

 

10 Bareket Street

Kiryat Matalon, P.O. Box 7537

Petach-Tikva 4951778, Israel

(Address of principal executive offices)

 

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

 

Form 20-F ☒    Form 40-F ☐

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____

 

 

 

 

 

 

On November 16, 2020, Can-Fite BioPharma Ltd. issued a press release entitled “Can-Fite Presented NASH Phase II Namodenoson Data at a Late Breaking Session of the American Association for the Study of Liver Diseases (AASLD) Conference”. A copy of this press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

 

1

 

 

Exhibit Index

 

Exhibit No.   Description
99.1     Press Release dated November 16, 2020

 

2

 

  

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

Date: November 16, 2020 By: /s/ Pnina Fishman
    Pnina Fishman
    Chief Executive Officer

 

 

3

 

 

Can Fite BioPharma (AMEX:CANF)
Historical Stock Chart
From Dec 2020 to Jan 2021 Click Here for more Can Fite BioPharma Charts.
Can Fite BioPharma (AMEX:CANF)
Historical Stock Chart
From Jan 2020 to Jan 2021 Click Here for more Can Fite BioPharma Charts.